603229.SS · 奥翔药业
China A-shares · RS rating 42 · As of 2026-10-14
| Price | 7.80 CNY |
|---|---|
| 1-day change | -1.6% |
| RS rating (overall / 1M / 3M / 12M) | 42 / 73 / 48 / 29 |
| Stage | Basing |
| Composite / Minervini / CANSLIM score | 20 / 19 / 14 |
| Industry group (rank) | Medical-Biomed/Biotech (68) |
| EPS growth Q/Q | – |
| Sales growth Q/Q | -48.5% |
| Distance from 52-week high | +26.3% |
| Market cap (USD) | $1.0B |